Saxagliptin, Dapagliflozin

Saxagliptin and Dapagliflozin is a combination medication used to treat type 2 diabetes in adults. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which helps increase the levels of insulin in the body, while Dapagliflozin is an SGLT2 inhibitor that helps the kidneys remove excess sugar through urine.
This dual-action therapy helps to effectively manage blood sugar levels, reducing the risk of complications associated with high blood sugar, such as heart disease, kidney disease, and nerve damage. It is prescribed for patients whose blood sugar is not adequately controlled with lifestyle changes and other medications, including metformin.
By lowering blood sugar levels, Saxagliptin and Dapagliflozin helps to improve glycemic control, which is essential in reducing the risk of diabetes-related complications. This medication does not cure diabetes, but rather helps manage the condition and its symptoms.
Patients should continue to monitor their blood sugar levels regularly, as well as follow a balanced diet and exercise regimen, to maximize the benefits of this medication. Healthcare professionals should closely monitor patients on this medication for potential side effects, such as urinary tract infections, genital yeast infections, and dehydration, which can be managed with appropriate care and follow-up.